treatment of glioma Lisapharma
growth of Lisapharma
market Edroma
new product
effective treatment
treatment cycle
Edroma medicinal product
Edroma innovation
HGG
potential market approximate
USA
years
malignant high-grade gliomas
alternative curative therapy
current brain-cancer therapy solutions
nanotechnology platform
clinical studies
business development
aggressive type of brain cancer
Lisapharmaâ€™s patented platform
Pre-clinical tests
unique business opportunity
satisfactory curative methods
tumour reduction
significant improvements
mice
terms of higher efficacy
nanoparticles
self-assembling procedure
foreseen ROI
industrialisation
prognosis
equipment
active ingredient zoledronic acid
increased life-expectancy
marketing
injection
dispersion
values
Italian pharmaceutical SME
internal return rate
lower toxicity
radiotherapy
orphan designation
patients
authorised provider
number of treatable cases
median survival
Novel nanomedicine
EMA
FDA
subjects
recent advances
complete cure
months
project
company turnover
total investment